CLSN's logo.
Ticker Symbol: CLSN

Imunon Inc

$0.81 - 20-12-2024 4 p.m. ET

Exchange: NASDAQ Country: US Currency: USD Asset Type: Common Stock CIK:0000749647

Company Profile

Celsion is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative cancer treatments, including immunotherapies and DNA-based therapies; and a platform for the development of nucleic acid vaccines currently focused on SARS-CoV2. The company's product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer. ThermoDox®, a proprietary heat-activated liposomal encapsulation of doxorubicin, is under investigator-sponsored development for several cancer indications. Celsion also has two feasibility stage platform technologies for the development of novel nucleic acid-based immunotherapies and other anti-cancer DNA or RNA therapies. Both are novel synthetic, non-viral vectors with demonstrated capability in nucleic acid cellular transfection.

Sector: Manufacturing
Industry: Pharmaceutical Preparation Manufacturing
Standard Industrial Classification Code (SIC code): 2834
Address: 997 Lenox Dr Ste 100
CEO: Michael Tardugno
Tags:
  • Health Technology
  • Medical Specialties
  • Manufacturing
  • Pharmaceutical Preparation Manufacturing

Pricing

Last Updated: December 31, 1969 07:00 PM EST
Previous Close: -
Change: - ( 0.00%)
Days Range: $1.92 - $2.00
Beta: 1.18
52wk. High: $15.75
52wk. Low: $1.80
Ytd. Change -75.80%
50 Day Moving Average: $2.29
200 Day Moving Average: $2.90
Shares Outstanding: 7098741

Valuation

Market Cap: 1.4B
PE Ratio: -0.46
EPS (TTM): -4.3

Dividends

Dividend Per Share (TTM): -
Dividend Yield (TTM): 0.00%
Ex-Dividend Date: N/A